Sidley advised Akeso Inc. on the deal.Akeso Inc. announced a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific antibody,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
